Paper42972023PubMed
Early temporal transcriptional and cytokine responses distinguish chemotherapy sensitivity in patient-derived xenograft models of triple-negative breast cancer.
Rinkenbaugh AL and 10 others. Oncogene, 2026.
Cite this record
ConductScience Library. Early temporal transcriptional and cytokine responses distinguish chemotherapy sensitivity in patient-derived xenograft models of triple-negative breast cancer. Papers, record 42972023. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42972023
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Early temporal transcriptional and cytokine responses distinguish chemotherapy sensitivity in patient-derived xenograft models of triple-negative breast cancer.
- Journal
- Oncogene
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-11-02
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| RP160710 | Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) | PubMed | PubMed | ||
| RR200009 | Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) | PubMed | PubMed | ||
| RP160710 | Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) | PubMed | PubMed | ||
| RP160710 | Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas) | PubMed | PubMed | ||
| P30CA016672 | U.S. Department of Health & Human Services | National Institutes of Health (NIH) | P30CA016672 | PubMed | NIH RePORTER |
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24882348 | Neoadjuvant therapy in the treatment of breast cancer. | Surg Oncol Clin N Am | 2014 | https://conductscience.org/library/papers/24882348 | PubMed |
| 2 | 32101663 | Pembrolizumab for Early Triple-Negative Breast Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32101663 | PubMed |
| 3 | 35139274 | Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35139274 | PubMed |
| 4 | 18250347 | Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18250347 | PubMed |
| 5 | 34902335 | Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/34902335 | PubMed |
| 6 | 32966830 | Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. | Lancet | 2020 | https://conductscience.org/library/papers/32966830 | PubMed |
| 7 | 21558518 | A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. | JAMA | 2011 | https://conductscience.org/library/papers/21558518 | PubMed |
| 8 | 21633166 | Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. | J Clin Invest | 2011 | https://conductscience.org/library/papers/21633166 | PubMed |
| 9 | 29378733 | Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29378733 | PubMed |
| 10 | 33599688 | Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2021 | https://conductscience.org/library/papers/33599688 | PubMed |
| 11 | 22235097 | Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22235097 | PubMed |
| 12 | 24356096 | Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. | Cancer Discov | 2014 | https://conductscience.org/library/papers/24356096 | PubMed |
| 13 | 26021444 | Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. | Breast Cancer Res | 2015 | https://conductscience.org/library/papers/26021444 | PubMed |
| 14 | 29681456 | Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. | Cell | 2018 | https://conductscience.org/library/papers/29681456 | PubMed |
| 15 | 36001024 | Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. | Cancer Discov | 2022 | https://conductscience.org/library/papers/36001024 | PubMed |
| 16 | 22039576 | Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. | Cancer Discov | 2011 | https://conductscience.org/library/papers/22039576 | PubMed |
| 17 | 26269531 | Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. | Cancer Res | 2015 | https://conductscience.org/library/papers/26269531 | PubMed |
| 18 | 27758887 | Tie2 Expression on Macrophages Is Required for Blood Vessel Reconstruction and Tumor Relapse after Chemotherapy. | Cancer Res | 2016 | https://conductscience.org/library/papers/27758887 | PubMed |
| 19 | 28916656 | Chemotherapy-Induced Macrophage Infiltration into Tumors Enhances Nanographene-Based Photodynamic Therapy. | Cancer Res | 2017 | https://conductscience.org/library/papers/28916656 | PubMed |
| 20 | 36727046 | The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy. | Front Oncol | 2022 | https://conductscience.org/library/papers/36727046 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42972023
GET https://conductscience.org/api/papers/v1/42972023/references?page=2